Clover Health Investments Future Growth
Future criteria checks 3/6
Clover Health Investments is forecast to grow earnings and revenue by 61.5% and 4.1% per annum respectively while EPS is expected to grow by 56% per annum.
Key information
61.5%
Earnings growth rate
56.0%
EPS growth rate
| Healthcare earnings growth | 20.9% |
| Revenue growth rate | 4.1% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 07 Nov 2024 |
Recent future growth updates
Recent updates
Clover Health: Buy The Dip, Reap The Rewards
Nov 18Clover Health Investments, Corp. (NASDAQ:CLOV) Just Reported Third-Quarter Earnings And Analysts Are Lifting Their Estimates
Nov 08
Clover Health's Rally: The Payoff Of A Profitable Pivot
Nov 06There's Reason For Concern Over Clover Health Investments, Corp.'s (NASDAQ:CLOV) Massive 37% Price Jump
Oct 03Clover Health: Changing Business Model, Seeking Profitability
Oct 03Clover Health: A Profitable Future Ahead Fueled By AI And Star Rating Success
Aug 15Clover Health Investments, Corp. (NASDAQ:CLOV) Surges 32% Yet Its Low P/S Is No Reason For Excitement
Aug 14Here's Why We're Watching Clover Health Investments' (NASDAQ:CLOV) Cash Burn Situation
Aug 06Clover Health Investments, Corp.'s (NASDAQ:CLOV) Price Is Right But Growth Is Lacking After Shares Rocket 26%
Jun 12Clover Health Investments, Corp.'s (NASDAQ:CLOV) 26% Dip In Price Shows Sentiment Is Matching Revenues
Apr 20Clover Health Investments, Corp. (NASDAQ:CLOV) Analysts Are Reducing Their Forecasts For This Year
Mar 16Will Clover Health Investments (NASDAQ:CLOV) Spend Its Cash Wisely?
Mar 06Clover Health: Its Luck May Have Ran Out
Feb 26Here's Why We're Not Too Worried About Clover Health Investments' (NASDAQ:CLOV) Cash Burn Situation
Nov 21We're Hopeful That Clover Health Investments (NASDAQ:CLOV) Will Use Its Cash Wisely
Jul 07Chamath Palihapitiya-linked Clover Health Investments trading near all-time low
Oct 14Chamath Palihapitiya cuts stake in Clover Health to under 5%
Oct 04Rethinking My Clover Health Position
Sep 12Clover Paid The Price Of Its Alleged Lies; Time To Move On
Aug 17Clover Health Investments to name president Andrew Toy as CEO
Aug 08Clover Health Is A Buy Ahead Of Earnings
Jul 29Clover Health to expand Medicare Advantage plans to 13 additional counties, exit 2
Jul 15Is Clover Health A Good Healthcare Sector Stock Pick?
Jun 30Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 1,896 | -26 | N/A | N/A | 3 |
| 12/31/2025 | 1,614 | -56 | N/A | N/A | 3 |
| 12/31/2024 | 1,382 | -60 | N/A | N/A | 3 |
| 9/30/2024 | 2,115 | -96 | -110 | -109 | N/A |
| 6/30/2024 | 2,090 | -121 | -178 | -177 | N/A |
| 3/31/2024 | 2,059 | -157 | -170 | -169 | N/A |
| 12/31/2023 | 2,036 | -213 | -116 | -116 | N/A |
| 9/30/2023 | 1,864 | -226 | -183 | -178 | N/A |
| 6/30/2023 | 2,441 | -268 | -63 | -58 | N/A |
| 3/31/2023 | 2,989 | -344 | -155 | -150 | N/A |
| 12/31/2022 | 3,579 | -340 | -291 | -286 | N/A |
| 9/30/2022 | 3,041 | -443 | -76 | -75 | N/A |
| 6/30/2022 | 2,564 | -402 | -222 | -222 | N/A |
| 3/31/2022 | 2,075 | -615 | -247 | -246 | N/A |
| 12/31/2021 | 1,361 | -588 | -283 | -282 | N/A |
| 9/30/2021 | 1,158 | -527 | -263 | -262 | N/A |
| 6/30/2021 | 922 | -487 | -252 | -252 | N/A |
| 3/31/2021 | 721 | -160 | -175 | -174 | N/A |
| 12/31/2020 | 690 | -136 | -119 | -118 | N/A |
| 9/30/2020 | 624 | -89 | -126 | -126 | N/A |
| 6/30/2020 | 572 | -145 | -116 | -116 | N/A |
| 3/31/2020 | 507 | -272 | -163 | -163 | N/A |
| 12/31/2019 | 455 | -364 | -160 | -160 | N/A |
| 12/31/2018 | 281 | -202 | -155 | -153 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CLOV is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.6%).
Earnings vs Market: CLOV is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: CLOV is expected to become profitable in the next 3 years.
Revenue vs Market: CLOV's revenue (4.1% per year) is forecast to grow slower than the US market (8.9% per year).
High Growth Revenue: CLOV's revenue (4.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if CLOV's Return on Equity is forecast to be high in 3 years time